{"id":3187,"date":"2018-03-29T19:56:20","date_gmt":"2018-03-29T19:56:20","guid":{"rendered":"http:\/\/blogs.sld.cu\/inorbib\/?p=3187"},"modified":"2018-03-29T19:56:20","modified_gmt":"2018-03-29T19:56:20","slug":"la-combinacion-de-atezolizumab-carboplatino-nab-paclitaxel-prolonga-la-ssp-en-nsclc","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/inorbib\/2018\/03\/29\/la-combinacion-de-atezolizumab-carboplatino-nab-paclitaxel-prolonga-la-ssp-en-nsclc\/","title":{"rendered":"LA COMBINACI\u00d3N DE ATEZOLIZUMAB, CARBOPLATINO, NAB-PACLITAXEL PROLONGA LA SSP EN NSCLC"},"content":{"rendered":"<p><strong>*LA COMBINACI\u00d3N DE ATEZOLIZUMAB, CARBOPLATINO, NAB-PACLITAXEL PROLONGA LA SSP EN NSCLC <\/strong><\/p>\n<ol>\n<li>Tomado de: Phase III IMpower131 study showed Genentech&#8217;s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer [news release]. San Francisco, CA: Genentech; March 19, 2018. <a href=\"https:\/\/www.gene.com\/media\/press-releases\/14709\/2018-03-19\/phase-iii-impower131-study-showed-genent\">https:\/\/www.gene.com\/media\/press-releases\/14709\/2018-03-19\/phase-iii-impower131-study-showed-genent<\/a>. Accessed March 19, 2018.Tomado : Lung Cancer Advisor . James Nam, PharmD<br \/>\n20 de marzo de 2018<\/li>\n<\/ol>\n<p><strong>\u00a0<\/strong><\/p>\n<p>El atezolizumab m\u00e1s carboplatino y nab-paclitaxel de primera l\u00ednea pueden mejorar la supervivencia libre de progresi\u00f3n (SLP) frente a la quimioterapia sola entre los pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPCNP) escamoso avanzado, seg\u00fan un comunicado de prensa.<\/p>\n<p>El atezolizumab, un inhibidor de la PD-L1, actualmente est\u00e1 aprobado para el carcinoma urotelial metast\u00e1sico \/ irresecable y el CPCNP metast\u00e1sico con mutaciones de EGFR o ALK refractarias a la quimioterapia basada en platino.<\/p>\n<p>Para el estudio abierto de fase 3 IMpower131 (Identificador ClinicalTrials.gov: NCT02367794), los investigadores asignaron aleatoriamente 1021 pacientes con CPCNP en estadio IV a 1 de 3 brazos del estudio: atezolizumab m\u00e1s carboplatino y paclitaxel (Grupo A), atezolizumab m\u00e1s carboplatino y nab- paclitaxel (Brazo B), o carboplatino y nab-paclitaxel solo (Brazo C, brazo de control).<\/p>\n<p>Todos los pacientes recibieron terapia de inducci\u00f3n durante 4 a 6 ciclos seguidos de monoterapia con atezolizumab de mantenimiento; los pacientes en el brazo de control solo recibieron la mejor atenci\u00f3n de apoyo.<\/p>\n<p>El perfil de seguridad de cada agente fue consistente con los reportados previamente; no se informaron nuevos eventos adversos cuando se administraron en combinaci\u00f3n.<\/p>\n<p>En el momento del an\u00e1lisis, no hubo mejoras significativas para la supervivencia global. Se presentar\u00e1n datos y hallazgos m\u00e1s maduros en una pr\u00f3xima conferencia de oncolog\u00eda.<\/p>\n<p><strong>Reference<\/strong><\/p>\n<ol>\n<li>Phase III IMpower131 study showed Genentech&#8217;s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer [news release]. San Francisco, CA: Genentech; March 19, 2018. <a href=\"https:\/\/www.gene.com\/media\/press-releases\/14709\/2018-03-19\/phase-iii-impower131-study-showed-genent\">https:\/\/www.gene.com\/media\/press-releases\/14709\/2018-03-19\/phase-iii-impower131-study-showed-genent<\/a>. Accessed March 19, 2018.<\/li>\n<\/ol>\n<p>Tomado de: Lung Cancer Advisor . James Nam, PharmD<br \/>\n20 de marzo de 2018<\/p>\n<p><em><span style=\"text-decoration: underline\">\u00a0<\/span><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>*LA COMBINACI\u00d3N DE ATEZOLIZUMAB, CARBOPLATINO, NAB-PACLITAXEL PROLONGA LA SSP EN NSCLC Tomado de: Phase III IMpower131 study showed Genentech&#8217;s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer [news release]. San Francisco, CA: Genentech; March [&hellip;]<\/p>\n","protected":false},"author":176,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts\/3187"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/users\/176"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/comments?post=3187"}],"version-history":[{"count":1,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts\/3187\/revisions"}],"predecessor-version":[{"id":3188,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/posts\/3187\/revisions\/3188"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/media?parent=3187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/categories?post=3187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/inorbib\/wp-json\/wp\/v2\/tags?post=3187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}